Mohsin Y. Meghji - 01 Oct 2023 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Reporting relationship: Director
Issuer ticker: BIAF
Reported as of: 01 Oct 2023
Net transaction value: +$18,750
SEC form: 4
Accepted by SEC: 24 Jan 2024, 20:52:41 UTC
Prior SEC filing: 22 Sep 2023
Next SEC filing: 31 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Mohsin Y Meghji

Key filing fact

Mohsin Y. Meghji filed Form 4 for bioAffinity Technologies, Inc. (BIAF) on 24 Jan 2024.

Key facts

This page summarizes Mohsin Y. Meghji's Form 4 filing for bioAffinity Technologies, Inc. (BIAF).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Jan 2024, 20:52.

Change

Previous filing in this sequence was filed on 22 Sep 2023.
Current net transaction value: +$18,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIAF transaction

Common Stock

Award

Transaction value: $18,750
Shares: +11,867
Change %: +12%
Price: $1.58
Shares after: 109,737
Date: 01 Oct 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mohsin Y. Meghji is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents a grant from the Issuer to Mr. Meghji of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.